Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance Akari Therapeutics stock opened at $2.24 on Thursday. The company has a 50-day moving average price of $3.23 and […]
More Stories
UFP Industries, Inc. (NASDAQ:UFPI) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of UFP Industries, Inc. (NASDAQ:UFPI – Get Free Report) have received an average recommendation of “Moderate Buy” from the...
Analysts Set Roku, Inc. (NASDAQ:ROKU) Price Target at $81.24
Roku, Inc. (NASDAQ:ROKU – Get Free Report) has received an average rating of “Hold” from the twenty-three research firms that...
Comparing Entera Bio (NASDAQ:ENTX) and Revolution Medicines (NASDAQ:RVMD)
Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both medical companies, but...
Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Recommendation of “Buy” from Brokerages
Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has earned an average recommendation of “Buy” from the eight brokerages...
Corus Entertainment Inc. (TSE:CJR.B) Receives Consensus Rating of “Strong Sell” from Analysts
Corus Entertainment Inc. (TSE:CJR.B – Get Free Report) has been assigned a consensus rating of “Strong Sell” from the six...
Sacks Parente Golf (SPGC) and Its Peers Head-To-Head Comparison
Sacks Parente Golf (NASDAQ:SPGC – Get Free Report) is one of 18 publicly-traded companies in the “Sporting & athletic goods,...